• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability

    4/16/25 8:35:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it has published its 2024 Corporate Sustainability Report, highlighting the company's efforts to build a sustainable and inclusive future.

    "iRhythm's core mission is to create a better world for patients by delivering better health and better insights through our trusted solutions and innovative technologies," said Sumi Shrishrimal, iRhythm's Chief Risk Officer and leader of Sustainability and Impact. "We accomplish this by being a responsible, ethical, and inclusive company dedicated to the highest standards of quality and excellence across our business as we execute upon our long-term strategic growth plan. I am so proud of the work our teams do every day, and our 2024 Corporate Sustainability Report reflects how we make cardiac monitoring more accessible, how we enable providers to better detect and prevent disease, and how we impact our communities as a global company."

    The 2024 Corporate Sustainability Report details sustainability accomplishments across four key pillars:

    • Quality and Sustainable Technology Innovation highlights include enhancing our quality systems, improving our customers' experience through Electronic Health Record (EHR) integration and innovative product launches, securing a strategic licensing agreement to advance connected patient care, and forming an Artificial Intelligence ("AI") Governance Steering Committee to address AI risks and opportunities in alignment with the company's strategic goals
    • Access and Health Equity highlights include expanding globally by launching commercially in four European countries (Austria, the Netherlands, Spain, and Switzerland) and receiving regulatory approval from the Japanese Pharmaceutical and Medical Device Agency for the Zio® 14-day, long-term continuous ECG monitoring system
    • Workforce and Inclusion highlights include refreshing our core values to define the workplace culture we would like to shape going forward, revising our code of conduct to provide employees with resources and guidance needed to operate with unquestionable integrity, and introducing new recognition opportunities to celebrate employees who elevate the company's values through their work
    • Environmental Impact highlights include completing inventory of Scope 3 greenhouse gas emissions, achieving 89.5% landfill waste diversion across our operations, obtaining ISO 14001:2015 Environmental Management Systems Certification, completing a life cycle analysis (LCA) of our products, and being named to Newsweek's list of America's Greenest Companies for 2025

    For more information about iRhythm's corporate sustainability efforts, please visit our Corporate Sustainability page here.

    About iRhythm Technologies

    iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. To learn more, please visit https://www.irhythmtech.com/.

    Investor Contact

    Stephanie Zhadkevich

    [email protected]

    Media Contact

    Kassandra Perry

    [email protected]



    Primary Logo

    Get the next $IRTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    2/7/2023$150.00Overweight
    Wells Fargo
    11/7/2022Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies to Participate in Upcoming Investor Conferences

      SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time)Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time)Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) Inter

      5/21/25 4:45:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection

      iRhythm Zio® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to JapanLaunch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise alongside an aging population1-3 SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio® long-term continuous ECG monitoring (LTCM) system, commercially introduced in thi

      5/1/25 4:10:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Announces First Quarter 2025 Financial Results

      SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

      5/1/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Financials

    Live finance-specific insights

    See more
    • iRhythm Technologies Announces First Quarter 2025 Financial Results

      SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

      5/1/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading di

      4/17/25 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

      SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023Cash, cash equ

      2/20/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/12/24 12:54:21 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/12/24 9:52:49 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

      SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      11/7/24 4:05:49 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IRTC
    SEC Filings

    See more
    • iRhythm upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

      5/2/25 8:03:46 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Wells Fargo resumed coverage on iRhythm with a new price target

      Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

      12/3/24 7:33:58 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on iRhythm with a new price target

      Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

      10/4/24 7:40:56 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Yoor Brian B was granted 1,358 shares, increasing direct ownership by 32% to 5,598 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      5/29/25 4:06:28 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Snyderman Ralph was granted 1,358 shares, increasing direct ownership by 11% to 13,288 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      5/29/25 4:04:54 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Bodaken Bruce G. was granted 1,358 shares, increasing direct ownership by 12% to 12,638 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      5/29/25 4:05:39 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      11/5/24 11:59:44 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      8/5/24 5:35:18 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

      4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

      12/6/23 7:08:38 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

      5/30/25 4:01:53 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by iRhythm Technologies Inc.

      SD - iRhythm Technologies, Inc. (0001388658) (Filer)

      5/21/25 4:02:02 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Technologies Inc.

      SCHEDULE 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

      5/13/25 11:32:29 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    See more
    • iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

      iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

      2/29/24 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Derrick Sung Joins Aerin Medical as Chief Financial Officer

      A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

      11/20/23 9:00:00 AM ET
      $IRTC
      $LUNG
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

      SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

      6/6/23 9:00:39 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care